Detail akcie Amgen Inc online

Business Summary: Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Amgen Inc revenues increased 9% to $8.15B. Net income totaled $1.73B vs. loss of $113M. Revenues reflect Other products segment increase of 20% to $1.65B, Repatha segment increase of 27% to $656M. Net Income reflects FV Adjustment of Financial Investments increase from $454M (expense) to $1.7B (income), Selling, general and administrative decrease of 7% to $1.69B (expense).